Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

被引：23

作者：

Kavanagh, John J. ^{[2
]}

Levenback, Charles F. ^{[2
]}

Ramirez, Pedro T. ^{[2
]}

Wolf, Judith L. ^{[2
]}

Moore, Carla L. ^{[2
]}

Jones, Marsha R. ^{[1
]}

Meng, Lisa ^{[1
]}

Brown, Gail L. ^{[1
]}

Bast, Robert C., Jr. ^{[2
]}

机构：

[1] Telik Inc, Palo Alto, CA USA

[2] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2010年 / 3卷

关键词：

GLUTATHIONE-S-TRANSFERASE; CARCINOMA; TOPOTECAN; RECURRENT; EFFICACY; PRODRUG; TLK286; TER286;

D O I：

10.1186/1756-8722-3-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m(2) in combination with PLD at 50 mg/m(2), intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Results: Canfosfamide plus PLD combination therapy was administered at 960/50 mg/m(2), respectively. Thirty-nine patients received a median number of 4 cycles (range 1.0-18.0). The ORR was 27.8% (95% CI, 14.2-45.2) with a disease stabilization rate of 80.6% (95% CI, 64.0-91.8) in the evaluable population. The CA-125 marker responses correlated with the radiological findings of complete response or partial response. The median PFS was 6.0 months (95% CI, 4.2-7.9) and median survival was 17.8 months. The combination was well tolerated. Myelosuppression was managed with dose reductions and growth factor support. Grade 3 febrile neutropenia was observed in 2 patients (5.1%). Non-hematologic adverse events occurred at the expected frequency and grade for each drug alone, with no unexpected or cumulative toxicities. Conclusions: Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer. A randomized phase 3 study was conducted based on this supportive phase 2 study.

引用

页数：11

共 33 条

[21]

OZOLS RF, 1997, PRINCIPLES PRACTICE, V2, P919

[22] Cellular response to a glutathione S-transferase P1-1 activated prodrug [J].

Rosario, LA ;

O'Brien, ML ;

Henderson, CJ ;

Wolf, CR ;

Tew, KD .

MOLECULAR PHARMACOLOGY, 2000, 58 (01) :167-174

[23]

ROSE P, 2007, P AN M AM SOC CLIN, pS281

[24] Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase [J].

Satyam, A ;

Hocker, MD ;

KaneMaguire, KA ;

Morgan, AS ;

Villar, HO ;

Lyttle, MH .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (08) :1736-1747

[25]

Tew KD, 1996, MOL PHARMACOL, V50, P149

[26]

Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205

[27]

THIGPEN T, 2006, FDA AM SOC CLIN ONC

[28]

Townsend DM, 2002, MOL CANCER THER, V1, P1089

[29] Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer [J].

Vergote, I. ;

Finkler, N. ;

del Campo, J. ;

Lohr, A. ;

Hunter, J. ;

Matei, D. ;

Kavanagh, J. ;

Vermorken, J. B. ;

Meng, L. ;

Jones, M. ;

Brown, G. ;

Kaye, S. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) :2324-2332

[30]

VERGOTE I, 2009, P AM SOC CLIN ONC MA, pS289

← 1 2 3 4 →